The global radiopharmaceutical CDMO market is anticipated to grow at an estimated rate of around 9% over the next five years.
On World Cancer Day 2026, Pakistan Atomic Energy Commission (PAEC) reiterated its commitment to providing accessible, affordable and ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...
GEHC Q4 2025 earnings call recap: revenue, record backlog, 2026 guidance, Intelerad deal, Flyrcado ramp, tariffs & China risks—read key takeaways.
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results